Gyros Protein Technologies introduces Gyrolab Generic Anti-AAV Kit to support gene therapy development Post author: Post published:June 17, 2024 Post category:uncategorized Ready-to-use kit enables detection of binding antibodies against AAV vectors without the need for serotype-specific assays. You Might Also Like Umbilical cord blood transplants improve cancer survival rates across all races October 1, 2024 Case Western Reserve University receives grant to investigate AML treatment for veterans October 15, 2024 Are younger women experiencing a higher incidence of breast cancer? January 31, 2024
Case Western Reserve University receives grant to investigate AML treatment for veterans October 15, 2024